Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes Article

Osei, K, Gaillard, T, Kaplow, J et al. (2004). Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes . 53(12), 1552-1557. 10.1016/j.metabol.2004.06.023

cited authors

  • Osei, K; Gaillard, T; Kaplow, J; Bullock, M; Schuster, D

authors

abstract

  • We examined the metabolic effects of rosiglitazone therapy on glucose control, insulin sensitivity, insulin secretion, and adiponectin in first-degree relatives of African Americans with type 2 diabetes (DM) with impaired glucose tolerance (IGT) and DM for 3 months. The study was comprised of 12 first-degree relatives with IGT, 17 newly diagnosed DM, and 19 healthy relatives with normal glucose tolerance (NGT). Oral glucose tolerance test (OGTT) was performed before and after 3 months of rosiglitazone therapy (4 to 8 mg/d) in patients with IGT and DM. Serum glucose, insulin, C-peptide, and adiponectin levels were measured before and 2 hours during OGTT in the NGT and patients with IGT and DM. Insulin resistance index (HOMA-IR) and β-cell function (HOMA-%B) were calculated in each subject using homeostasis model assessment (HOMA). Rosglitazone improved the overall glycemic control in the IGT and DM groups. Following rosiglitazone, the β-cell secretion remained unchanged, while HOMR-IR was reduced in DM by 30% (4.12 ± 1.95 v 6.33 ± 3.54, P < .05) and the IGT group (3.78 ± 2.45 v 4.81 ± 3.49, P = not significant [NS]). Mean plasma adiponectin levels were significantly (P < .05) lower in the DM (6.74 ± 1.95 μg/mL) when compared with the NGT group(9.61 ± 5.09). Rosiglitazone significantly (P < .001) increased adiponectin levels by 2-fold in patients with IGT (22.2 ± 10.97 μg/mL) and 2.5-fold greater in DM (15.68 ± 8.23 μg/mL) at 3 months when compared with the 0 month. We conclude that adiponectin could play a significant role (1) in the pathogenesis of IGT and DM and (2) the beneficial metabolic effects of thiazolidinediones (TZDs) in high-risk African American patients. © 2004 Elsevier Inc. All rights reserved.

publication date

  • December 1, 2004

Digital Object Identifier (DOI)

start page

  • 1552

end page

  • 1557

volume

  • 53

issue

  • 12